Highlight Therapeutics' Marisol Quintero talks to Proactive London's Katie Pilbeam about their intention to extend the benefit of immunotherapies for patients who are not benefiting right now.
Quintero explains the plans for clinical trials of its lead product candidate BO-112.
The company recently announced that they have entered a second Phase II trial collaboration with a subsidiary of Merck & Co. And there are currently three ongoing trials in total.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Highlight Therapeutics named herein, including the promotion by the Company of Highlight Therapeutics in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update. Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year. He...
Prev article
